Phasebio Pharmaceuticals Inc(PHAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAS Phasebio Pharmaceuticals Inc

Trading 03-13 10:15:38 EDT

0.0701

+0.0000

0.00%

High0.0701	Low0.0701	Vol0.00
Open0.0701	D1 Closing0.0701	Amplitude0.00%
Mkt Cap3.50M	Tradable Cap2.41M	Total Shares49.86M
T/O0.00	T/O Rate0.00%	Tradable Shares34.41M
P/B-0.03	ROE-3091.02%	EPS-2.12
52wk High1.38	52wk Low0.0665	P/E-0.03
Dividend0.00	Div.Yield0.00	ROA-106.07%

暂无数据

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PHAS","market":"US","secType":"STK","nameCN":"Phasebio Pharmaceuticals Inc","latestPrice":0.0701,"timestamp":1683316800000,"preClose":0.0701,"halted":0,"volume":0,"delay":0,"floatShares":34410934,"shares":49858116,"eps":-2.118926,"marketStatus":"Trading","change":0,"latestTime":"03-13 10:15:38 EDT","open":0.0701,"high":0.0701,"low":0.0701,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.118926,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1741896000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1539835200000,"exchange":"NASDAQ","adjPreClose":0.0701,"volumeRatio":0},"requestUrl":"/m/hq/s/PHAS","defaultTab":"news","newsList":[{"id":"2271173619","title":"PhaseBio Pharmaceuticals Cut to Hold From Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2271173619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2271173619?lang=en_us&edition=full_marsco","pubTime":"2022-09-29 00:46","pubTimestamp":1664383560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHAS"],"gpt_icon":0},{"id":"2270951784","title":"PhaseBio Might Have To Return Global Rights To Its Lead Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2270951784","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2270951784?lang=en_us&edition=full_marsco","pubTime":"2022-09-28 21:06","pubTimestamp":1664370380,"startTime":"0","endTime":"0","summary":"\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/22/09/29049003/phasebio-might-have-to-return-global-rights-to-its-lead-program","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4007","PSQ","BK4139","QQQ","PHAS","QID","SQQQ","MNQmain",".IXIC","TQQQ","AZN","BK4568","QLD"],"gpt_icon":0},{"id":"2270807788","title":"PhaseBio Pharmaceuticals Cut to Market Perform From Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2270807788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2270807788?lang=en_us&edition=full_marsco","pubTime":"2022-09-28 18:23","pubTimestamp":1664360580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS","BK4139"],"gpt_icon":0},{"id":"2249536723","title":"BRIEF-Phasebio Pharmaceuticals Says Received A Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2249536723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2249536723?lang=en_us&edition=full_marsco","pubTime":"2022-07-06 04:47","pubTimestamp":1657054052,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS","BK4124","SMP"],"gpt_icon":0},{"id":"2235400126","title":"PhaseBio Pharmaceuticals: Q1 Earnings Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2235400126","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235400126?lang=en_us&edition=full_marsco","pubTime":"2022-05-16 19:54","pubTimestamp":1652702076,"startTime":"0","endTime":"0","summary":" \n\nPhaseBio Pharmaceuticals (NASDAQ:PHAS) reported its Q1 earnings results on Monday, May 16, 2022 at 06:00 AM.\n\nHere&#39;s what investors need to know about the announcement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/22/05/27216239/phasebio-pharmaceuticals-q1-earnings-insights","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS"],"gpt_icon":0},{"id":"2235289694","title":"PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2235289694","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235289694?lang=en_us&edition=full_marsco","pubTime":"2022-05-16 19:15","pubTimestamp":1652699711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R8B4awdI246EbZIDm2Hv5Q--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R8B4awdI246EbZIDm2Hv5Q--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phasebio-pharmaceuticals-phas-reports-q1-111511070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PTN","PHAS"],"gpt_icon":0},{"id":"2235062494","title":"PhaseBio Pharmaceuticals Q1 EPS $(0.23) Up From $(0.87) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2235062494","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235062494?lang=en_us&edition=full_marsco","pubTime":"2022-05-16 18:07","pubTimestamp":1652695658,"startTime":"0","endTime":"0","summary":"PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.23) per share. This is a 73.56 percent increase over losses of $(0.87) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/22/05/27213920/phasebio-pharmaceuticals-q1-eps-0-23-up-from-0-87-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAS"],"gpt_icon":0},{"id":"2235409324","title":"Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2235409324","media":"T-Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2235409324?lang=en_us&edition=full_marsco","pubTime":"2022-05-16 18:03","pubTimestamp":1652695380,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABP","CGEM","LHDX","ONTF","BK4023","BK4007","BK4139","SANA","BK4196","APR","PHAS","BK4082"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phasebio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.076},{"period":"3month","weight":-0.0752},{"period":"6month","weight":-0.0056},{"period":"1year","weight":0.0814},{"period":"ytd","weight":-0.0464}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.040973},{"month":2,"riseRate":0.2,"avgChangeRate":-0.124917},{"month":3,"riseRate":0.4,"avgChangeRate":0.371332},{"month":4,"riseRate":0.4,"avgChangeRate":0.06721},{"month":5,"riseRate":0.4,"avgChangeRate":0.025307},{"month":6,"riseRate":0.5,"avgChangeRate":-0.032346},{"month":7,"riseRate":0.25,"avgChangeRate":0.068841},{"month":8,"riseRate":0.25,"avgChangeRate":-0.014805},{"month":9,"riseRate":0,"avgChangeRate":-0.37053},{"month":10,"riseRate":0.25,"avgChangeRate":-0.110027},{"month":11,"riseRate":0.2,"avgChangeRate":-0.204981},{"month":12,"riseRate":0.6,"avgChangeRate":0.219493}],"exchange":"NASDAQ","name":"Phasebio Pharmaceuticals Inc","nameEN":"Phasebio Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phasebio Pharmaceuticals Inc(PHAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phasebio Pharmaceuticals Inc(PHAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phasebio Pharmaceuticals Inc,PHAS,Phasebio Pharmaceuticals Inc股票,Phasebio Pharmaceuticals Inc股票老虎,Phasebio Pharmaceuticals Inc股票老虎国际,Phasebio Pharmaceuticals Inc行情,Phasebio Pharmaceuticals Inc股票行情,Phasebio Pharmaceuticals Inc股价,Phasebio Pharmaceuticals Inc股市,Phasebio Pharmaceuticals Inc股票价格,Phasebio Pharmaceuticals Inc股票交易,Phasebio Pharmaceuticals Inc股票购买,Phasebio Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phasebio Pharmaceuticals Inc(PHAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phasebio Pharmaceuticals Inc(PHAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}